Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study

P. D. Delmas, S. Adami, C. Strugala, J. A. Stakkestad, J. Y. Reginster, D. Felsenberg, C. Christiansen, R. Civitelli, R. R. Recker, M. Bolognese, C. Hughes, D. Masanauskaite, P. Ward, P. Sambrook, David M Reid

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis.

Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 m g every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability.

Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function.

Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

Original languageEnglish
Pages (from-to)1838-1846
Number of pages8
JournalArthritis & Rheumatism
Volume54
Issue number6
DOIs
Publication statusPublished - Jun 2006

Keywords

  • VERTEBRAL FRACTURE RISK
  • RANDOMIZED-TRIAL
  • ZOLEDRONIC ACID
  • RENAL-FAILURE
  • DOUBLE-BLIND
  • RISEDRONATE
  • BONE
  • BISPHOSPHONATE
  • ALENDRONATE
  • BM-21.0955

Cite this

Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J. Y., Felsenberg, D., ... Reid, D. M. (2006). Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study. Arthritis & Rheumatism, 54(6), 1838-1846. https://doi.org/10.1002/art.21918

Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study. / Delmas, P. D.; Adami, S.; Strugala, C.; Stakkestad, J. A.; Reginster, J. Y.; Felsenberg, D.; Christiansen, C.; Civitelli, R.; Recker, R. R.; Bolognese, M.; Hughes, C.; Masanauskaite, D.; Ward, P.; Sambrook, P.; Reid, David M.

In: Arthritis & Rheumatism, Vol. 54, No. 6, 06.2006, p. 1838-1846.

Research output: Contribution to journalArticle

Delmas, PD, Adami, S, Strugala, C, Stakkestad, JA, Reginster, JY, Felsenberg, D, Christiansen, C, Civitelli, R, Recker, RR, Bolognese, M, Hughes, C, Masanauskaite, D, Ward, P, Sambrook, P & Reid, DM 2006, 'Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study', Arthritis & Rheumatism, vol. 54, no. 6, pp. 1838-1846. https://doi.org/10.1002/art.21918
Delmas, P. D. ; Adami, S. ; Strugala, C. ; Stakkestad, J. A. ; Reginster, J. Y. ; Felsenberg, D. ; Christiansen, C. ; Civitelli, R. ; Recker, R. R. ; Bolognese, M. ; Hughes, C. ; Masanauskaite, D. ; Ward, P. ; Sambrook, P. ; Reid, David M. / Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study. In: Arthritis & Rheumatism. 2006 ; Vol. 54, No. 6. pp. 1838-1846.
@article{76b533742e5e47dd80adc54537a46bfa,
title = "Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study",
abstract = "Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis.Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 m g every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability.Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1{\%} among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8{\%} among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8{\%} among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function.Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.",
keywords = "VERTEBRAL FRACTURE RISK, RANDOMIZED-TRIAL, ZOLEDRONIC ACID, RENAL-FAILURE, DOUBLE-BLIND, RISEDRONATE, BONE, BISPHOSPHONATE, ALENDRONATE, BM-21.0955",
author = "Delmas, {P. D.} and S. Adami and C. Strugala and Stakkestad, {J. A.} and Reginster, {J. Y.} and D. Felsenberg and C. Christiansen and R. Civitelli and Recker, {R. R.} and M. Bolognese and C. Hughes and D. Masanauskaite and P. Ward and P. Sambrook and Reid, {David M}",
year = "2006",
month = "6",
doi = "10.1002/art.21918",
language = "English",
volume = "54",
pages = "1838--1846",
journal = "Arthritis & Rheumatism",
issn = "0004-3591",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Intravenous ibandronate injections in postmenopausal osteoporosis: One-year results from the dosing intravenous administration study

AU - Delmas, P. D.

AU - Adami, S.

AU - Strugala, C.

AU - Stakkestad, J. A.

AU - Reginster, J. Y.

AU - Felsenberg, D.

AU - Christiansen, C.

AU - Civitelli, R.

AU - Recker, R. R.

AU - Bolognese, M.

AU - Hughes, C.

AU - Masanauskaite, D.

AU - Ward, P.

AU - Sambrook, P.

AU - Reid, David M

PY - 2006/6

Y1 - 2006/6

N2 - Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis.Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 m g every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability.Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function.Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

AB - Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis.Methods. In a randomized, double-blind, double-dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 m g every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55-80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2-L4] bone mineral density [BMD] T score less than -2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C-telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability.Results. At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior (P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function.Conclusion. As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated.

KW - VERTEBRAL FRACTURE RISK

KW - RANDOMIZED-TRIAL

KW - ZOLEDRONIC ACID

KW - RENAL-FAILURE

KW - DOUBLE-BLIND

KW - RISEDRONATE

KW - BONE

KW - BISPHOSPHONATE

KW - ALENDRONATE

KW - BM-21.0955

U2 - 10.1002/art.21918

DO - 10.1002/art.21918

M3 - Article

VL - 54

SP - 1838

EP - 1846

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

SN - 0004-3591

IS - 6

ER -